MSGV1-PSCA-8T28Z

Phase 1Biologic

HH. Lee Moffitt Cancer Center and Research Institute

MSGV1-PSCA-8T28Z is one of 3 biologic programs targeting Stem Cell. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stem CellRecruiting

Stem CellPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Stem Cell

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 2

2 2

Cytoxan

BBaxter Healthcare Corporation

Phase 2

3 3

MSGV1-PSCA-8T28Z

HH. Lee Moffitt Cancer Center and Research Institute

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2033

Phase 1Recruiting

Stem Cell

NCT06193486

Clinical

Trials by Indication[1]

Stem Cell1 trial

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06193486·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MSGV1-PSCA-8T28Z. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MSGV1-PSCA-8T28Z compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MSGV1-PSCA-8T28Z. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — H. Lee Moffitt Cancer Center and Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: HH. Lee Moffitt Cancer Center and Research Institute

MSGV1-PSCA-8T28Z

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2033

Trials by Indication[1]

Stem Cell1 trial

References

Drug Info

Quick Facts

Related News